Dupilumab for Post-Hematopoietic Cell Transplantation Dermatitis in Wiskott-Aldrich Syndrome
- 29 May 2023
- journal article
- letter
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 43 (7) , 1526-1528
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- A Case of Two Adult Brothers with Wiskott-Aldrich Syndrome, One Treated with Gene Therapy and One with HLA-Identical Hematopoietic Stem Cell TransplantationJournal of Clinical Immunology, 2021
- Actin Dynamics at the T Cell Synapse as Revealed by Immune-Related ActinopathiesFrontiers in Cell and Developmental Biology, 2021
- Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC reportBlood, 2020
- Efficacy of Dupilumab for Controlling Severe Atopic Dermatitis in a Patient with Hyper-IgE SyndromeJournal of Clinical Immunology, 2020
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisNew England Journal of Medicine, 2016
- Wiskott-Aldrich Syndrome: Diagnosis, Clinical and Laboratory Manifestations, and TreatmentTransplantation and Cellular Therapy, 2009